Open Science Research Excellence
%0 Journal Article
%A Congo Tak Shing Ching and  Hong-Sheng Chen and  Tai-Ping Sun and  Hsiu-Li Shieh
%D 2012 
%J  International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering
%B World Academy of Science, Engineering and Technology
%I International Science Index 66, 2012
%T An Immunosensor for Bladder Cancer Screening
%U http://waset.org/publications/8651
%V 66
%X Nuclear matrix protein 22 (NMP22) is a FDA approved
biomarker for bladder cancer. The objective of this study is to develop
a simple NMP22 immumosensor (NMP22-IMS) for accurate
measurement of NMP22. The NMP22-IMS was constructed with
NMP22 antibody immobilized on screen-printed carbon electrodes.
The construction procedures and antibody immobilization are simple.
Results showed that the NMP22-IMS has an excellent (r2³0.95)
response range (20 – 100 ng/mL). In conclusion, a simple and reliable
NMP22-IMS was developed, capable of precisely determining urine
NMP22 level.
%P 246 - 248